NCT02616874View on ClinicalTrials.gov

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

October 30, 2017

Conditions
HIV
Interventions
DRUG

MVA.HIVconsv vaccine

Dose: 2x10e8 pfu, Interval: weeks 0 and 9.

DRUG

Romidepsin

Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5

Trial Locations (2)

08916

Germans Trias i Pujol Hospital, Badalona

08036

Clinic Hospital, Barcelona

All Listed Sponsors
collaborator

Germans Trias i Pujol Hospital

OTHER

collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

Hospital de Sant Pau

OTHER

collaborator

HIVACAT

UNKNOWN

collaborator

University of Oxford

OTHER

collaborator

BCN Checkpoint

INDUSTRY

lead

IrsiCaixa

OTHER

NCT02616874 - Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals | Biotech Hunter | Biotech Hunter